Listening, discerning, negotiating, and finding common interests.”
Ted hull genova diagnostics how to#
“Life Sciences investing is not just about recognizing good science,” Papiernik says, “it’s about people - learning how to interact with co-investors, limited partners, and entrepreneurs. Scott and his team at LSI have conducted numerous market research projects for top medical device manufacturers including Johnson & Johnson, Medtronic, Boston Scientific, Abbott, Becton Dickinson, Teleflex, Cardinal Health, GE Healthcare, and Stryker, among others.Īntoine Papiernik is Chairman and Managing Partner at Sofinnova Partners, which he joined in 1997. He has held leadership roles as a strategic partner for Elsevier Business Intelligence, Health Research Intelligence, and Informa Business Intelligence. Prior to founding LSI, he held senior executive roles with renowned life science data providers including Medical Data International, Medtech Insight and Windhover Information. He has been in the medtech market intelligence business for over 20 years supporting venture funded startups, major strategics, and life science investors as they navigate the ever-changing medtech marketplace. Scott is the President, CEO and Founder of Life Science Intelligence. Scott's mission at the meeting will be to connect the investors, innovators and strategics that are driving the future of medtech. For more information, please visit will join his team of exclusive sponsors to host the Emerging Medtech Summit. FFC invests in established companies in the middle market with significant growth opportunities, backs proven management teams, and then leverages its comprehensive healthcare network and value creation model to accelerate growth and build market leading and strategically valuable companies. Since its founding in 1995, FFC has invested over $900 million in 36 portfolio companies.
About Ferrer Freeman & Company, LLCįerrer Freeman & Company, LLC is a private equity firm located in Greenwich, CT focused on making growth capital investments in healthcare companies. Goodwin Procter served as legal advisor to Genova. Genova was advised by Lazard Middle Market. We wish the Company and its new financial partner success in this exciting next phase of growth.” Ted Lundberg, Partner at FFC added, “The partnership with Genova’s management team has been unique and rewarding. We believe the Company is well positioned to continue on its growth trajectory into the future under LLCP’s ownership.”Ĭhris Crosby, Managing Director at Nautic said, “We want to thank the management team and employees of Genova for all of their hard work and effort to make Genova a great company, one that serves physicians and their patients in the quest to identify and treat chronic disease.” We operated as partners and succeeded together. Ted Hull, Chairman and CEO of Genova said, “On behalf of the Company, I’d like to thank Nautic and FFC for their partnership in building the Company to where it is today.
It currently serves more than 10,000 primary care physicians, specialists and other healthcare providers. The Company offers more than 125 specialized diagnostic assessments that cover digestive, metabolic, immunology, endocrinology and other physiological areas. Genova, founded in 1986, is a global specialty clinical laboratory that has pioneered a unique, systems-based approach to testing that supports the personalized treatment and prevention of chronic disease. (“Genova” or the “Company”) to Levine Leichtman Capital Partners (“LLCP”) and members of Genova management. Nautic Partners, LLC (“Nautic”) and Ferrer Freeman & Company, LLC (“FFC”) announced the sale of Asheville, NC-based Genova Diagnostics, Inc.
0 kommentar(er)
